ABB Completes Acquisition of B&R
ABB today announced that it has completed its acquisition of B&R (Bernecker + Rainer Industrie-Elektronik GmbH), the largest independent provider focused on product- and software-based, open-architecture solutions for machine and factory automation worldwide. The transaction, which was announced on April 4, 2017, is financed in cash and expected to be operationally EPS accretive in the first year.
“I am very pleased to now officially welcome B&R to ABB. This transaction closes ABB’s historic gap in machine and factory automation and expands our leadership in industrial automation. Following the acquisition of B&R, we are the only industrial automation provider offering customers in process and discrete industries the entire spectrum of technology and software solutions around measurement, control, actuation, robotics, digitalization and electrification,” said ABB CEO Ulrich Spiesshofer. “This combination will open new global growth opportunities by expanding our offerings to existing clients while also bringing ABB’s broad reach, extensive domain knowledge and deep technical expertise to industries and customers that we have not served before. Our commitment to growing the business of B&R is demonstrated by our investment in a new R&D center, which is to be built next to its headquarters in upper Austria.”
This transaction marks another important milestone in ABB’s Next Level strategy. With the acquisition of B&R, ABB strengthens its position as the second-largest industrial automation player globally. ABB is now uniquely positioned to seize the tremendous growth opportunities created by the Fourth Industrial Revolution. B&R’s industry-leading products, software and services in Programmable Logic Controllers (PLC), Industrial PCs and servo motion-based machine and factory automation ideally complement ABB’s industrial automation portfolio for utilities, industry and transport & infrastructure providers.
Through the acquisition of B&R, ABB is taking another major step in expanding its digital offering by combining its industry-leading portfolio of digital solutions, ABB Ability™, with B&R's strong application and software platforms, its large installed base, customer access, and tailored automation solutions.
“There is a strong cultural fit between B&R and ABB, including our shared commitment to customer-centric, open-architecture software and solutions. This will ensure a smooth integration as we combine our strengths and maximize our uniquely comprehensive offering for the benefit of our customers,” said Peter Terwiesch, President of ABB’s Industrial Automation division.
With the closing of the transaction, B&R becomes part of ABB’s Industrial Automation division as a new global business unit called Machine & Factory Automation, integrating ABB’s PLC activities. The unit is headquartered in Eggelsberg, Austria, ABB’s new global center for machine and factory automation, and is headed by Hans Wimmer, former Managing Director of B&R. The co-founders of B&R, Erwin Bernecker and Josef Rainer, will act as advisors during the integration process. ABB is committed to investing further in the expansion of B&R’s operations, including R&D, and to building on the company’s successful business model. This ambition is also reflected in the mid-term sales target for B&R of more than $1 billion.
“The B&R team is proud to be part of ABB and its leading Industrial Automation division,” said Hans Wimmer, the Managing Director of ABB’s new Machine & Factory Automation business unit. “With our compatible cultures, complementary strengths and leading technologies, ABB and B&R will have an even more compelling value proposition to offer our customers in the Fourth Industrial Revolution.”
The experienced team of professionals from B&R will become an integral part of ABB’s Industrial Automation division team. The integration is led by a dedicated team located in Austria including team members from both sides. ABB will follow a proven integration process to ensure a seamless integration in line with the key objectives of the transaction.
ABB (ABBN: SIX Swiss Ex) is a pioneering technology leader in electrification products, robotics and motion, industrial automation and power grids, serving customers in utilities, industry and transport & infrastructure globally. Continuing more than a 125-year history of innovation, ABB today is writing the future of industrial digitalization and driving the Energy and Fourth Industrial Revolutions. ABB operates in more than 100 countries with about 132,000 employees. www.abb.com
Important notice about forward-looking information
This press release contains "forward-looking statements" relating to the acquisition of B&R by ABB. Such forward-looking statements can be identified by words such as target, ambition, plans, intends, expects and other similar terms. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the acquisition will be completed, or if it is completed, that it will close within the anticipated time period or that the expected benefits of the acquisition will be realized. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect ABB's business, particularly those identified in the cautionary factors discussion in ABB's Annual Report on Form 20-F for the year ended December 31, 2016. ABB undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F24.4.2018 23:30 | Tiedote
Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2017 “Document de Référence” for the year ended December 31, 2017, including the management report and the annual financial report with the “Autorité des Marchés Financiers (AMF)” and its Annual Report on Form 20-F for the year ended December 31, 2017 with the U.S. Securities and Exchange Commission (SEC). These documents can be accessed on the Investors section of the Company’s corporate website (www.erytech.com). In addition, the “Document de Référence” is also available on the AMF’s website (http://www.amf-france.org) and the Annual Report on Form 20-F is also available on the SEC’s website (www.sec.gov). Printed copies of these documents are also
Rimini Street Launches New Solutions that Further Extend the Life and Value of Enterprise Software as a Foundation for Innovation24.4.2018 19:00 | Tiedote
Rimini Street, Inc . (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the first offerings in a family of solutions designed to provide improved competitive advantage to organizations with mature and valuable enterprise software investments that can be used as a foundation for innovation. Rimini Street’s new solutions can enable an organization to quickly and cost-effectively modernize their current enterprise software with the latest desired features and capabilities, future-proof their technical platforms against yet-unknown technology changes, and secure their systems against a constantly evolving threat environment. Rimini Street’s new solutions enable organizations to leverage their existing systems as a solid foundation for an innovative hybrid IT strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/
Novaliq to Present Scientific and Clinical Research During the 2018 Association for Research in Vision and Ophthalmology Meeting in Honolulu, HI24.4.2018 18:53 | Tiedote
Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Meeting in Honolulu, HI (April 29-May 3). The variety of data to be presented reflects Novaliq’s dedication to science and clinical research. With the collection of posters, Novaliq will share clinical and pre-clinical data on its EyeSol® drug delivery technology and provide insights into the mode of action of its NOV03/NovaTears® water-free therapy for the treatment of dry eye disease (DED). Furthermore, Novaliq will present its first pre-clinical efficacy data in glaucoma. Scientific posters supported by Novaliq will include: “Influence of perfluorohexyloctane containing eye drops on tear film thickness in patients with mild to moderate dry eye disease.” Authors: Garhöfer G., Schm
PPG Reports Sustainability Progress, New 2025 Goals24.4.2018 16:07 | Tiedote
PPG (NYSE:PPG) today released its 2017 Corporate Sustainability Report, which details the company’s continued progress in strengthening its sustainable operations in 2017 and the launch of new, aggressive sustainability goals it aims to achieve by 2025. The report is available at sustainability.ppg.com. “PPG’s sustainability efforts go beyond product innovations to extend to our customers’ operations and the communities in which we operate,” said Mark Cancilla, PPG vice president, environment, health and safety. “We are encouraged by our progress in 2017 and excited about our new goals, which are representative of the challenges and opportunities of our current business portfolio.” The company achieved the following progress in 2017: 32 percent of sales from products that provide customers with a sustainable advantage, an increase of 60 percent since 2012. This includes the unveiling of multiple products that provide a sustainable solution, such as Sigma Air Pure, a revolutionary bio-b
WeQ Launches to Transform Mobile Ad Tech with Human Intelligence and Inclusivity24.4.2018 16:00 | Tiedote
WeQ, a mobile ad tech brand providing user acquisition and engagement services at a global scale, announced today its official launch. WeQ is driven by a forward-thinking, socio-economic movement striving to shift from an exclusive ‘I’ culture to a collaborative ‘We’ culture. Setting its sights on becoming a trusted leader in the mobile ad tech industry, WeQ combines innovative data-driven technology with the collective human intelligence of its accomplished team of mobile ad tech experts to empower companies to reach their goals. WeQ comes out of the gate armed with a strategic investment, having secured more than $50 million USD in internal funds and debt capital to accelerate an ambitious global growth path. The ad tech brand plans to use the funds as it undertakes an aggressive M&A strategy. Over the next 12-24 months, WeQ plans to acquire cutting-edge technologies from innovative ventures to expand its technological footprint and services, attract international talent, and enter n
Bioiberica Approves Its Combined Drug for Osteoarthritis in Five More European Countries24.4.2018 15:17 | Tiedote
Bioiberica's combination of chondroitin sulphate and glucosamine hydrochloride, a slow action drug to treat osteoarthritis symptoms, was approved as an ethical drug in France, Austria, Hungary, Poland, and Finland through a mutual recognition process from Spain. ‘This approval confirms that Drug Agencies from different countries attest to the effectiveness and safety of the combination of pharmaceutical grade chondroitin sulphate and glucosamine hydrochloride. This drug has proven to reduce pain and improve mobility in people affected by knee osteoarthritis which, due to its safety profile, could also be used as an alternative by those patients with cardiovascular or gastrointestinal problems who should not be prescribed anti-inflammatory drugs chronically’, stated Dr Juan Gispert, Bioiberica's R&D director. The principle study that guarantees its effectiveness is the MOVES clinical trial, published in the Annals of the Rheumatic Diseases, which concludes that the combination of chondr
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme